

## RECARBRIO - (EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL ; Powder)

<b>Generic Name</b>	CILASTATIN SODIUM; IMIPENEM; RELEBACTAM	<b>Innovator</b>	Merck
<b>Dosage</b>	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL ; Powder	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: ? Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) ? Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ? Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.